INTRODUCTION: Angiosarcomas are rare malignant endothelial cell tumors which have up-regulation of the angiopoietin system [e.g., Tie2 and Angiopoietin 2 (Ang2)]. Trebananib is a novel agent targeting Angiopoietin 1 and Angiopoietin 2. METHODS: Trebananib 30 mg/kg was administered weekly until progressive disease or unacceptable toxicity. The primary endpoint was response rate by RECIST v1.1. Correlatives included: (1) baseline tumor expression of Ang2/Tie2 by immunohistochemistry, (2) serum levels of Ang1 and Ang2, (3) pre- and post-treatment phospho-receptor tyrosine kinase and (4) MYC/FLT-4 amplification status. RESULTS: Sixteen patients were enrolled [median age 68 years (24-91), 38 % male, median number of prior therapies 2.5 (1-7)]. No responses were observed in 12 evaluable patients. Estimated median and 12-week progression-free survival rate were 7 weeks (95 % 6-8) and 25 % (95 % CI 11-58 %), respectively. Median overall survival was 28 weeks (95 % CI 17-48). There were two (12.5 %) patients who experienced grade 3 adverse event and one (6.3 %) patient who experienced grade 4 adverse event that was considered at least possibly related to treatment. CONCLUSIONS: Trebananib was well tolerated. Lack of response in the first stage of a Simon 2 stage design led to closure of this study. Prolonged PFS was observed in four pts, lasting 3.4-5.5 months.
INTRODUCTION:Angiosarcomas are rare malignant endothelial cell tumors which have up-regulation of the angiopoietin system [e.g., Tie2 and Angiopoietin 2 (Ang2)]. Trebananib is a novel agent targeting Angiopoietin 1 and Angiopoietin 2. METHODS: Trebananib 30 mg/kg was administered weekly until progressive disease or unacceptable toxicity. The primary endpoint was response rate by RECIST v1.1. Correlatives included: (1) baseline tumor expression of Ang2/Tie2 by immunohistochemistry, (2) serum levels of Ang1 and Ang2, (3) pre- and post-treatment phospho-receptor tyrosine kinase and (4) MYC/FLT-4 amplification status. RESULTS: Sixteen patients were enrolled [median age 68 years (24-91), 38 % male, median number of prior therapies 2.5 (1-7)]. No responses were observed in 12 evaluable patients. Estimated median and 12-week progression-free survival rate were 7 weeks (95 % 6-8) and 25 % (95 % CI 11-58 %), respectively. Median overall survival was 28 weeks (95 % CI 17-48). There were two (12.5 %) patients who experienced grade 3 adverse event and one (6.3 %) patient who experienced grade 4 adverse event that was considered at least possibly related to treatment. CONCLUSIONS: Trebananib was well tolerated. Lack of response in the first stage of a Simon 2 stage design led to closure of this study. Prolonged PFS was observed in four pts, lasting 3.4-5.5 months.
Authors: J Partanen; E Armstrong; T P Mäkelä; J Korhonen; M Sandberg; R Renkonen; S Knuutila; K Huebner; K Alitalo Journal: Mol Cell Biol Date: 1992-04 Impact factor: 4.272
Authors: Matthew G Fury; Cristina R Antonescu; Kimberly J Van Zee; Murray F Brennan; Robert G Maki Journal: Cancer J Date: 2005 May-Jun Impact factor: 3.360
Authors: Thomas Hawighorst; Mihaela Skobe; Michael Streit; Young-Kwon Hong; Paula Velasco; Lawrence F Brown; Lucia Riccardi; Bernhard Lange-Asschenfeldt; Michael Detmar Journal: Am J Pathol Date: 2002-04 Impact factor: 4.307
Authors: Oliver Stoeltzing; Syed A Ahmad; Wenbiao Liu; Marya F McCarty; Jane S Wey; Alexander A Parikh; Fan Fan; Niels Reinmuth; Michiya Kawaguchi; Corazon D Bucana; Lee M Ellis Journal: Cancer Res Date: 2003-06-15 Impact factor: 12.701
Authors: Rajesh Ramanathan; Amy L Olex; Mikhail Dozmorov; Harry D Bear; Leopoldo Jose Fernandez; Kazuaki Takabe Journal: Breast Cancer Res Treat Date: 2017-01-06 Impact factor: 4.872
Authors: Swati Shrestha; Carolyn Meyers; Jia Shen; Paulina Giacomelli; Michelle A Scott; Chia Soo; Sarah M Dry; Kang Ting; Aaron W James Journal: J Orthop Date: 2016-12-27
Authors: Marie Viala; Marie Vinches; Marie Alexandre; Caroline Mollevi; Anna Durigova; Nadia Hayaoui; Krisztian Homicsko; Alice Cuenant; Céline Gongora; Luca Gianni; Diego Tosi Journal: Br J Cancer Date: 2018-02-13 Impact factor: 7.640
Authors: Swati Shrestha; Jia Shen; Paulina Giacomelli; Michelle A Scott; Chia Soo; Kang Ting; Bruno Péault; Sarah M Dry; Aaron W James Journal: J Orthop Date: 2016-11-28
Authors: Loïc Lebellec; François Bertucci; Emmanuelle Tresch-Bruneel; Isabelle Ray-Coquard; Axel Le Cesne; Emmanuelle Bompas; Jean-Yves Blay; Antoine Italiano; Olivier Mir; Thomas Ryckewaert; Yves Toiron; Luc Camoin; Anthony Goncalves; Nicolas Penel; Marie-Cécile Le Deley Journal: BMC Cancer Date: 2018-10-11 Impact factor: 4.430
Authors: Roberto Carmagnani Pestana; Manal M Hassan; Reham Abdel-Wahab; Yehia I Abugabal; Lauren M Girard; Donghui Li; Ping Chang; Kanwal Raghav; Jeff Morris; Robert A Wolff; Asif Rashid; Hesham M Amin; Ahmed Kaseb Journal: Oncotarget Date: 2018-12-28